Media coverage about CASI Pharmaceuticals (NASDAQ:CASI) has been trending somewhat positive recently, according to Accern Sentiment Analysis. The research group identifies negative and positive press coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. CASI Pharmaceuticals earned a daily sentiment score of 0.19 on Accern’s scale. Accern also assigned media headlines about the biotechnology company an impact score of 45.2137082426716 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.

Shares of CASI Pharmaceuticals (NASDAQ CASI) traded down 3.21% during mid-day trading on Tuesday, hitting $1.81. The stock had a trading volume of 299,113 shares. The company has a 50 day moving average price of $1.04 and a 200 day moving average price of $1.12. The firm’s market cap is $108.95 million. CASI Pharmaceuticals has a 12-month low of $0.91 and a 12-month high of $1.99.

CASI Pharmaceuticals (NASDAQ:CASI) last issued its quarterly earnings results on Monday, August 14th. The biotechnology company reported ($0.04) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.03) by ($0.01). Equities analysts forecast that CASI Pharmaceuticals will post ($0.15) earnings per share for the current fiscal year.

Several research firms have weighed in on CASI. HC Wainwright reissued a “buy” rating and issued a $2.00 target price on shares of CASI Pharmaceuticals in a report on Friday, September 8th. Maxim Group set a $4.00 target price on CASI Pharmaceuticals and gave the company a “buy” rating in a report on Monday, August 14th. Finally, ValuEngine lowered CASI Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, July 22nd.

WARNING: This piece was first published by Watch List News and is owned by of Watch List News. If you are accessing this piece on another domain, it was illegally stolen and republished in violation of United States and international copyright & trademark laws. The original version of this piece can be viewed at

In related news, Director Wei-Wu He bought 315,327 shares of the firm’s stock in a transaction that occurred on Friday, September 15th. The shares were acquired at an average cost of $1.33 per share, for a total transaction of $419,384.91. Following the acquisition, the director now directly owns 212,323 shares of the company’s stock, valued at approximately $282,389.59. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 13.01% of the company’s stock.

About CASI Pharmaceuticals

CASI Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of therapeutics for cancer and other medical needs. It operates through the development of targeted therapeutics for the treatment of cancer segment. Its product pipeline includes internal development of its lead drug candidate, ENMD-2076; MARQIBO, ZEVALIN and EVOMELA, and early-stage candidates in preclinical development.

Insider Buying and Selling by Quarter for CASI Pharmaceuticals (NASDAQ:CASI)

Receive News & Ratings for CASI Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CASI Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.